1
|
Oghalaie A, Shoari A, Kazemi-Lomedasht F, Rahimi-Jamnani F, Mahboudi F, Ghaderi H, Hosseininejad-Chafi M, Moazzami R, Ashja Ardalan A, Piri-Gavgani S, Shahbazzadeh D, Behdani M. Development of polyclonal heavy chain antibodies targeting programmed death ligand-1. Vet Res Forum 2023; 14:323-328. [PMID: 37383651 PMCID: PMC10298837 DOI: 10.30466/vrf.2022.553274.3461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Accepted: 06/27/2022] [Indexed: 06/30/2023]
Abstract
Programmed death ligand-1 (PD-L1, CD274 and B7-H1) has been described as a ligand for immune inhibitory receptor programmed death protein 1 (PD-1). With binding to PD-1 on activated T cells, PD-L1 can prevent T cell responses via motivating apoptosis. Consequently, it causes cancers immune evasion and helps the tumor growth; hence, PD-L1 is regarded as a therapeutic target for malignant cancers. The anti-PD-L1 monoclonal antibody targeting PD-1/PD-L1 immune checkpoint has attained remarkable outcomes in clinical application and has turned to one of the most prevalent anti-cancer drugs. The present study aimed to develop polyclonal heavy chain antibodies targeting PD-L1via Camelus dromedarius immunization. The extra-cellular domain of human PD-L1 (hPD-L1) protein was cloned, expressed, and purified. Afterwards, this recombinant protein was utilized as an antigen for camel immunization to acquire polyclonal camelid sera versus this protein. Our outcomes showed that hPD-L1 protein was effectively expressed in the prokaryotic system. The antibody-based techniques, such as enzyme-linked immunosorbent assay, western blotting, and flow cytometry displayed that the hPD-L1 protein was detected by generated polyclonal antibody. Due to the advantages of multi-epitope-binding ability, our study exhibited that camelid antibody is effective to be applied significantly for detection of PD-L1 protein in essential antibody-based studies.
Collapse
Affiliation(s)
- Akbar Oghalaie
- Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran;
| | - Alireza Shoari
- Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran;
| | - Fatemeh Kazemi-Lomedasht
- Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran;
| | - Fatemeh Rahimi-Jamnani
- Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran;
| | | | - Hajarossadat Ghaderi
- Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran;
| | - Mohammad Hosseininejad-Chafi
- Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran;
| | - Reza Moazzami
- Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;
| | - Arghavan Ashja Ardalan
- Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran;
| | - Somayeh Piri-Gavgani
- Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran;
| | - Delavar Shahbazzadeh
- Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran;
| | - Mahdi Behdani
- Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran;
- Zoonoses Research Center, Pasteur Institute of Iran, Amol, Iran.
| |
Collapse
|
2
|
Alimohammadi R, Porgoo M, Eftekhary M, Kiaie SH, Ansari Dezfouli E, Dehghani M, Nasrollahi K, Malekshahabi T, Heidari M, Pouya S, Alimohammadi M, Sattari Khavas D, Modaresi MS, Ghasemi MH, Ramyar H, Mohammadipour F, Hamzelouei F, Mofayezi A, Mottaghi SS, Rahmati A, Razzaznian M, Tirandazi V, Tat M, Borzouee F, Sadeghi H, Haji Mohammadi M, Rastegar L, Safar Sajadi SM, Ehsanbakhsh H, Bazmbar H, Baghernejadan Z, Shams Nouraei M, Pazooki P, Pahlavanneshan M, Alishah K, Nasiri F, Mokhberian N, Mohammadi SS, Akar S, Niknam H, Azizi M, Ajoudanian M, Moteallehi-Ardakani MH, Mousavi Shaegh SA, Ramezani R, Salimi V, Moazzami R, Hashemi SM, Dehghanizadeh S, Khoddami V. SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN ®, induces robust humoral and cellular immunity in mice and non-human primates. NPJ Vaccines 2022; 7:105. [PMID: 36056015 PMCID: PMC9438359 DOI: 10.1038/s41541-022-00528-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Accepted: 08/12/2022] [Indexed: 11/09/2022] Open
Abstract
At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN®; a vaccine candidate against SARS-CoV-2 infection. COReNAPCIN® is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and rhesus macaque with COReNAPCIN® induced strong humoral responses with high titers of virus-binding and neutralizing antibodies. Upon vaccination, a robust SARS-CoV-2 specific cellular immunity was also observed in both mice and non-human primate models. Additionally, vaccination protected rhesus macaques from symptomatic SARS-CoV-2 infection and pathological damage to the lung upon challenging the animals with high viral loads of up to 2 × 108 live viral particles. Overall, our data provide supporting evidence for COReNAPCIN® as a potent vaccine candidate against SARS-CoV-2 infection for clinical studies.
Collapse
Affiliation(s)
| | - Meysam Porgoo
- Department of Process Engineering, ReNAP Therapeutics, Tehran, Iran
| | | | | | | | - Maryam Dehghani
- Department of Process Engineering, ReNAP Therapeutics, Tehran, Iran
| | - Kaveh Nasrollahi
- Department of Genetic Engineering, ReNAP Therapeutics, Tehran, Iran
| | | | - Maryam Heidari
- Department of Immunology, ReNAP Therapeutics, Tehran, Iran
| | - Sedigheh Pouya
- Department of Immunology, ReNAP Therapeutics, Tehran, Iran
| | | | | | | | | | - Hamed Ramyar
- Department of Process Engineering, ReNAP Therapeutics, Tehran, Iran
| | | | | | | | | | | | | | - Vista Tirandazi
- Department of Quality Control, ReNAP Therapeutics, Tehran, Iran
| | - Mahdi Tat
- Department of Genetic Engineering, ReNAP Therapeutics, Tehran, Iran
| | - Fatemeh Borzouee
- Department of Protein Engineering, ReNAP Therapeutics, Tehran, Iran
| | - Hossein Sadeghi
- Department of Protein Engineering, ReNAP Therapeutics, Tehran, Iran
| | | | - Leila Rastegar
- Department of Chemistry, ReNAP Therapeutics, Tehran, Iran
| | | | | | - Hamed Bazmbar
- Department of Process Engineering, ReNAP Therapeutics, Tehran, Iran
| | | | | | - Pouya Pazooki
- Department of Quality Control, ReNAP Therapeutics, Tehran, Iran
| | | | - Khadijeh Alishah
- Department of Genetic Engineering, ReNAP Therapeutics, Tehran, Iran
| | - Fateme Nasiri
- Department of Quality Control, ReNAP Therapeutics, Tehran, Iran
| | - Neda Mokhberian
- Department of Quality Control, ReNAP Therapeutics, Tehran, Iran
| | | | - Shima Akar
- Rizsamaneh Behboud Darman, Mashhad Medical Technologies Science Park, Mashhad, Iran
| | - Hamidreza Niknam
- Rizsamaneh Behboud Darman, Mashhad Medical Technologies Science Park, Mashhad, Iran
| | - Marzieh Azizi
- Department of Protein Engineering, ReNAP Therapeutics, Tehran, Iran
| | | | | | - Seyed Ali Mousavi Shaegh
- Rizsamaneh Behboud Darman, Mashhad Medical Technologies Science Park, Mashhad, Iran.,Laboratory of Microfluidics and Medical Microsystems, BuAli Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Reihaneh Ramezani
- Department of Formulation Development, ReNAP Therapeutics, Tehran, Iran.,Department of Family Therapy, Women Research Center, Alzahra University, Tehran, Iran
| | - Vahid Salimi
- Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Reza Moazzami
- Department of Protein Engineering, ReNAP Therapeutics, Tehran, Iran
| | - Seyed Mahmoud Hashemi
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | - Vahid Khoddami
- ReNAP Therapeutics, Tehran, Iran. .,Pediatric Cell and Gene Therapy Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
4
|
Hosseininejad-Chafi M, Alirahimi E, Ramezani B, Oghalaie A, Sotoudeh N, Ghaderi H, Kazemi-Lomedasht F, Habibi-Anbouhi M, Moazzami R, Behdani M. In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin. Iran J Basic Med Sci 2022; 25:27-31. [PMID: 35656448 PMCID: PMC9118281 DOI: 10.22038/ijbms.2021.54293.12195] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Accepted: 10/31/2021] [Indexed: 12/14/2022]
Abstract
Objectives A variety of signaling molecules have been identified that play a role in angiogenesis, of prime importance, vascular endothelial growth factor (VEGF) and its resceptor (VEGFR), which is highly expressed in most human solid tumors. Targeting VEGF or/and VEGFR with immunotoxin may be a promising approach to directly affect cancer cells. Immunotoxins are for targeted treatment comprising two functional moieties, an antibody that binds to target cells along with toxin that kills molecules. Materials and Methods In this study, an immunotoxin comprising domain of diphtheria toxin subunit A (DT386) genetically fused to mouse VEGF (mVEGF-DT) was developed. The second construct, which contains the DT386 domain, was made to investigate the action of the DT386 domain on tumor cells. Both gene constructs were cloned, expressed, and were further purified. The biological activity of mVEGF-DT and DT386 proteins was assessed on the TC1 cell line bearing mouse model. Proteins were injected intra-tumoral in mice, in separate groups. Results Tumors in the mVEGF-DT group started to dwindle after six injections, but tumor size in both control groups (DT386 and PBS), continued to grow. Conclusion Successful targeting of solid tumor cells by mVEGF-DT immunotoxin demonstrates the therapeutic potential utility of these conjugates for tumor targeting.
Collapse
Affiliation(s)
| | - Ehsan Alirahimi
- Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
| | - Behzad Ramezani
- Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
| | - Akbar Oghalaie
- Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
| | - Nazli Sotoudeh
- Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
| | - Hajarsadat Ghaderi
- Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
| | - Fatemeh Kazemi-Lomedasht
- Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
| | | | - Reza Moazzami
- Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Mahdi Behdani
- Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
5
|
Naddafi F, Shirazi FH, Talebkhan Y, Tabarzad M, Barkhordari F, Aliabadi Farahani Z, Bayat E, Moazzami R, Mahboudi F, Davami F. A comparative study of the bispecific monoclonal antibody, blinatumomab expression in CHO cells and E. coli. Prep Biochem Biotechnol 2018; 48:961-967. [PMID: 30461361 DOI: 10.1080/10826068.2018.1525562] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The "bispecifics" market improved over the past decade due to the development of many technological platforms including bispecific T cell engagers (BiTEs). The approval of blinatumomab, the most advanced bispecific T-cell engager (BiTE) in clinical trials, can be a significant milestone in the development of bispecific antibodies. Both Chinese hamster ovary (CHO) cells and E. coli strain are considered as the most widely used hosts for the large-scale production of therapeutic monoclonal antibodies. Since both of the economic and qualitative aspects of protein production are important in industry, selection of a suitable protein expression system is very critical. The BsAb gene was cloned into the expression vectors FC550A-1, pcDNA3.1 (+), and PET22b and 6 × His-tagged BsAb then purified on a Ni-NTA chromatography column. Both SDS-PAGE and Western blotting analysis of the purified protein demonstrated that blinatumomab was successfully expressed as a 55 kDa in both expression systems. The antigen-binding properties of blinatumomab were compared in the mammalian system versus Escherichia coli. The results showed that the purified antibody from a mammalian expression system has better binding activity than the one from E. coli host.
Collapse
Affiliation(s)
- Fatemeh Naddafi
- a Pharmaceutical Sciences Research Center , Shahid Beheshti University of Medical Sciences , Tehran , Iran
| | - Farshad H Shirazi
- a Pharmaceutical Sciences Research Center , Shahid Beheshti University of Medical Sciences , Tehran , Iran
| | - Yeganeh Talebkhan
- b Biotechnology Research Center , Pasteur Institute of Iran , Tehran , Iran
| | - Maryam Tabarzad
- c Protein Technology Research Center , Shahid Beheshti University of Medical Sciences , Tehran , Iran
| | | | - Zahra Aliabadi Farahani
- b Biotechnology Research Center , Pasteur Institute of Iran , Tehran , Iran.,d Department of Biology, Science and Research Branch , Islamic Azad University , Tehran , Iran
| | - Elham Bayat
- b Biotechnology Research Center , Pasteur Institute of Iran , Tehran , Iran.,e Department of Molecular and Cellular Sciences, Faculty of Advanced Science and Technology, Pharmaceutical Sciences Branch , Islamic Azad University , Tehran , Iran
| | - Reza Moazzami
- b Biotechnology Research Center , Pasteur Institute of Iran , Tehran , Iran
| | - Fereidoun Mahboudi
- b Biotechnology Research Center , Pasteur Institute of Iran , Tehran , Iran
| | - Fatemeh Davami
- b Biotechnology Research Center , Pasteur Institute of Iran , Tehran , Iran
| |
Collapse
|